The Cooper Companies, Inc. (NASDAQ:COO) Stock Holdings Decreased by Handelsbanken Fonder AB

Handelsbanken Fonder AB cut its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 30.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 437,662 shares of the medical device company's stock after selling 189,860 shares during the period. Handelsbanken Fonder AB owned 0.22% of Cooper Companies worth $36,917,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. OFI Invest Asset Management acquired a new position in Cooper Companies in the 4th quarter valued at approximately $34,000. City Holding Co. bought a new stake in Cooper Companies during the 1st quarter valued at $34,000. New Age Alpha Advisors LLC bought a new stake in Cooper Companies during the 4th quarter worth approximately $38,000. Covestor Ltd lifted its stake in Cooper Companies by 35.5% during the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company's stock valued at $42,000 after acquiring an additional 120 shares in the last quarter. Finally, Atala Financial Inc purchased a new position in Cooper Companies during the fourth quarter worth about $51,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Price Performance

Shares of COO traded down $0.52 during trading hours on Thursday, reaching $70.90. The company had a trading volume of 533,197 shares, compared to its average volume of 1,598,745. The firm has a 50 day simple moving average of $78.01 and a 200-day simple moving average of $86.81. The Cooper Companies, Inc. has a 12-month low of $65.00 and a 12-month high of $112.38. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $14.18 billion, a price-to-earnings ratio of 36.36, a PEG ratio of 2.25 and a beta of 0.98.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its earnings results on Thursday, May 29th. The medical device company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.93 by $0.03. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $995.12 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.85 earnings per share. Research analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on COO. BNP Paribas upgraded Cooper Companies to a "hold" rating in a research report on Thursday, March 13th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $76.00 price target (down from $110.00) on shares of Cooper Companies in a research note on Friday, May 30th. Needham & Company LLC restated a "hold" rating on shares of Cooper Companies in a report on Thursday, May 22nd. Wall Street Zen cut Cooper Companies from a "buy" rating to a "hold" rating in a research note on Saturday, June 7th. Finally, Stifel Nicolaus cut their price target on shares of Cooper Companies from $115.00 to $105.00 and set a "buy" rating on the stock in a report on Friday, March 7th. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, Cooper Companies currently has a consensus rating of "Moderate Buy" and an average target price of $100.38.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.